ICARIA-MM: Infusion-related reactions* were mostly mild to moderate for patients receiving SARCLISA¹

Adapted from SARCLISA Summary of Product Characteristics.¹

• All patients who experienced infusion-related reactions, experienced them during the 1st infusion¹
• Infusion-related reactions were resolved on the same day in most patients, and all were reversible¹
• No delayed infusion-related reactions were observed and no mandatory post-infusion corticosteroid prophylaxis^1,2

The most common symptoms of an infusion-related reaction included dyspnoea, cough, chills, and nausea. The most common severe signs and symptoms included hypertension and dyspnoea. The adverse event of severe anaphylactic reaction has been reported as a serious infusion reaction in 5 patients (0.3%) based on data from multiple clinical trials investigating isatuximab.¹

In patients who experience grade 2 (moderate) infusion-related reactions, a temporary interruption in the infusion should be considered.¹